TY - JOUR
T1 - Comprehensive secondary analysis of thrombotic events in pediatric patients receiving extracorporeal membrane oxygenation
T2 - A prospective cohort study
AU - Hughes, Tyler B.
AU - Treffalls, Rebecca N.
AU - Koek, Wouter
AU - Dalton, Heidi
AU - Karam, Oliver
AU - Meyer, Andrew D.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024
Y1 - 2024
N2 - Introduction: This study aims to describe laboratory and clinical factors associated with thrombotic events during prolonged pediatric extracorporeal membrane oxygenation. Methods: A secondary analysis of a multi-center prospective study performed between 2012 and 2014. Patients under the age of 19 years that received extracorporeal membrane oxygenation for at least 4 days of therapy were included (n = 385). Univariable analysis and binomial regression were performed to evaluate predictive factors of single and multiple thrombotic events. A posteriori scoring tool was created to categorize thrombotic event severity. Results: Over 39% of children receiving prolonged ECMO experienced a thrombotic event (TE). Binomial regression demonstrated an association between higher transfused platelet volume (mL/kg) (OR 1.04, CI: 95% 1.01–1.06, p = 0.003), Anti-Xa (OR 5.38, CI: 95% 1.22–23.8, p = 0.026) and aPTT (OR 1.01, CI: 95% 1.00–1.02, p = 0.032) the day prior to TE. Patients experiencing multiple TEs were associated with higher platelet transfusion volume (mL/kg) (OR 1.08, CI: 95% 1.05–1.12, p =< 0.001), antithrombin III (OR 1.03, CI: 95% 1.01–1.04, p = 0.001) and aPTT (OR 1.02, CI: 95% 1.01–1.03, p = 0.009). Patients experiencing multiple thrombotic events had a higher risk of 28-day mortality based on a cumulative clot severity score >4 (OR 2.37 (CI: 95% 1.32–4.24). Conclusions: Current lab tests show limited sensitivity to predict these events the day prior in a vulnerable patient group, leading to potential ECMO circuit failures. Patients with multiple thrombotic events during ECMO therapy face increased mortality risks, highlighting the need for dynamic reporting tools like clot severity scores and detailed documentation of interventions to enhance understanding and improve outcomes.
AB - Introduction: This study aims to describe laboratory and clinical factors associated with thrombotic events during prolonged pediatric extracorporeal membrane oxygenation. Methods: A secondary analysis of a multi-center prospective study performed between 2012 and 2014. Patients under the age of 19 years that received extracorporeal membrane oxygenation for at least 4 days of therapy were included (n = 385). Univariable analysis and binomial regression were performed to evaluate predictive factors of single and multiple thrombotic events. A posteriori scoring tool was created to categorize thrombotic event severity. Results: Over 39% of children receiving prolonged ECMO experienced a thrombotic event (TE). Binomial regression demonstrated an association between higher transfused platelet volume (mL/kg) (OR 1.04, CI: 95% 1.01–1.06, p = 0.003), Anti-Xa (OR 5.38, CI: 95% 1.22–23.8, p = 0.026) and aPTT (OR 1.01, CI: 95% 1.00–1.02, p = 0.032) the day prior to TE. Patients experiencing multiple TEs were associated with higher platelet transfusion volume (mL/kg) (OR 1.08, CI: 95% 1.05–1.12, p =< 0.001), antithrombin III (OR 1.03, CI: 95% 1.01–1.04, p = 0.001) and aPTT (OR 1.02, CI: 95% 1.01–1.03, p = 0.009). Patients experiencing multiple thrombotic events had a higher risk of 28-day mortality based on a cumulative clot severity score >4 (OR 2.37 (CI: 95% 1.32–4.24). Conclusions: Current lab tests show limited sensitivity to predict these events the day prior in a vulnerable patient group, leading to potential ECMO circuit failures. Patients with multiple thrombotic events during ECMO therapy face increased mortality risks, highlighting the need for dynamic reporting tools like clot severity scores and detailed documentation of interventions to enhance understanding and improve outcomes.
KW - extracorporeal membrane oxygenation
KW - thrombosis risk
KW - thrombosis, pediatric
KW - transfusion, mortality
UR - http://www.scopus.com/inward/record.url?scp=85205672052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85205672052&partnerID=8YFLogxK
U2 - 10.1177/02676591241289358
DO - 10.1177/02676591241289358
M3 - Article
C2 - 39352407
AN - SCOPUS:85205672052
SN - 0267-6591
JO - Perfusion (United Kingdom)
JF - Perfusion (United Kingdom)
ER -